Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Circassia's Harris Deeply Frustrated By Phase III Cat Allergy Flop

Executive Summary

The UK biotech’s potential revolutionary approach to allergies has failed to achieve its primary endpoint in a Phase III study, halting much of its research in the allergy area and casting a shadow over UK innovation.

Advertisement

Related Content

Phase III Beckons For A Short-Course Seasonal Allergic Rhinitis Jab
Circassia Builds US Respiratory Presence with AstraZeneca Deal
UK Health-Care Investors ‘Not As Brave Or Audacious’ As Those In US
KO’d By Allergy Failure, Circassia Looks To Respiratory Pipeline For Second Wind
Turmoil In Allergy Market Continues As Merck Ends ALK Partnership
Gloom Is Overblown: Allergy Vaccine Sector Is Poised To Globalize
Stockwatch: Damage Not Controlled
Circassia Uses Adaptive Design For Phase III And Advances Commercial Plans
Circassia paying £188m for two asthma firms, but it's still an allergy specialist
Circassia puts money where mouth is; IPO floats at top price

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065453

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel